A young woman with clear cell adenocarcinoma of the uterine cervix.
In May 1999, an 18-year-old woman visited a physician because of vaginal bleeding and the excretion of large clots from the vagina. A vaginal tumor was discovered and the patient was referred to our outpatient department. Vaginal examination showed a bleeding, tumor, approximately 6 cm in size, protruding from the cervical os and filling the vagina. The cytological finding of the uterine cervix was class V, and the histological diagnosis by punch biopsy was clear cell adenocarcinoma (CCAC) of the uterine cervix. The patient initially received neoadjuvant chemotherapy (NAC) with intraarterial injections of 8 mg/m(2) of mitomycin, 270 mg/m(2) of etoposide, and 380 mg/m(2) of carboplatin. Although the NAC reduced the size of the tumor, it failed to produce favorable pathological changes and was therefore deemed ineffective. A radical abdominal hysterectomy and pelvic lymphadenectomy were performed on October 12. Macroscopic findings showed a tumor, 6 cm in diameter, growing from the right side of the uterine cervix, with a fragile, necrotic surface. Pathological diagnosis was CCAC of the cervix (pT2a, N0, M0). The patient was discharged from our hospital without any postoperative chemotherapy or radiation therapy. No signs of recurrence have been detected since. We reviewed the literature on CCAC patients in Japan up to the present and compared the data with the data reported in a review of CCAC in the Netherlands. While there were similarities between the patients in the two countries in the patients' pattern of growth and the poor prognosis of the tumors, there was a significant difference between the countries in the patients' history of diethylstilbestrol (DES) exposure. These results suggest that menarche and menopause may play roles in promoting carcinogenesis, or alternatively, that a subpopulation of women are subject to genetic or exogenous risk factors other than DES.
Seki
Hiroyuki
H
Department of Obstetrics and Gynecology, Kantou Rousai Hospital, 2035 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan. h-n-seki@theia.ocn.ne.jp
Takada
Toshio
T
Sodemoto
Takeo
T
Hoshino
Hiromi
H
Saitoh
Kazuo
K
Uekusa
Toshimasa
T
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D000293:Adolescent; D017668:Age of Onset; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002273:Carcinogens / Q000009:adverse effects; D004054:Diethylstilbestrol / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007564:Japan; D008197:Lymph Node Excision; D016685:Mitomycin / Q000008:administration & dosage; D020360:Neoadjuvant Therapy; D009426:Netherlands; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery
D002273:Carcinogens; D016685:Mitomycin; D005047:Etoposide; D004054:Diethylstilbestrol; D016190:Carboplatin